PathoQuest is a biotech company developing NGS-based metagenomic tests for exhaustive identification of pathogens.
PathoQuest has raised $17.4M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
PathoQuest's investors include Kurma Partners, Eurazeo, Verve Ventures, Charles River Laboratories International, Idinvest Partners.
PathoQuest is headquartered in Paris, France.
PathoQuest is a biotech company developing NGS-based metagenomic tests for exhaustive identification of pathogens.
PathoQuest is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PathoQuest — Funding & Investors." VCBacked, November 9, 2021, https://www.vcbacked.co/company/pathoquest. Accessed August 15, 2026.
VCBacked. (2021). PathoQuest — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/pathoquest
{{cite web |title=PathoQuest — Funding & Investors |url=https://www.vcbacked.co/company/pathoquest |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated